Use of Adjuvants in Vaccines to Offer Lucrative Growth Prospects
The growing usage of integrated unit vaccinations is propelling the adjuvant industry forward. The need for different adjuvants is increasing as consumption rises. More development is projected in the next years, which will raise the need for adjuvants. The market is predicted to develop at a modest pace, owing to the rising use of biologics and biosimilars, as well as increased R&D in vaccines throughout the globe. Unmet demand for specialised vaccinations, higher government immunisation recommendations, technical advancements, and greater usage of combination and synthetic vaccines are all factors that contribute to the development of the adjuvants vaccine market.
Growing Vaccination Awareness to Boost Market Growth
Over the past years, national and local bodies have taken efforts to aware public of benefits of vaccine immunization. The media plays an important role in spreading awareness among the general public regarding pros and cons of vaccine immunization. With the growing level of medica coverage in rural parts of developing and under-developed economies, the market for live vaccines is anticipated to witness lucrative opportunities over the forecast period.
What are the Growth Drivers for Vaccine Sales Market?
• Rising Focus and Government Support on Immunization Programs
• Growing Investment in Vaccine Development
• Increasing Company Initiatives to Enhance Vaccine R&D
• High Prevalence of Infectious Diseases
• Technological Advancements in Vaccine Administration
• Rapid Need of Immunization
• Strong Supply Backed Up by Robust R&D to Drive the Market
What are the Challenges for Vaccine Sales Market?
• Inadequate Reimbursement Coverage
• High Cost of Vaccine Development
• Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
• Stringent Government Regulations for Approval
What are the Market Opportunities?
• High Growth Prospects in Emerging Markets
• Focus on Therapeutic Vaccines
• Use of Adjuvants in Vaccines
• Government Support for Future Vaccine R&D
Long Timelines of Vaccine Manufacturing Projected to Hinder Vaccines Market Growth
Vaccine development is seen as an expensive, difficult, and time-consuming process because to the intricacy of manufacturing and accompanying processes, which may take up to 10–15 years. Due to the endless combinations of biological ingredients, microorganisms, equipment employed, ambient conditions, and culture stages, results may vary greatly throughout manufacturing. Furthermore, the reagents and procedures needed to monitor culture parameters add to the process’ complexity, prolonging production times.
Furthermore, product approvals from regulatory bodies take longer since the authorities evaluate the product’s quality and effectiveness, as well as the manufacturing process. After the producers show enough pre-clinical evidence on the vaccines’ safety to confirm the vaccines’ action in people, the vaccines start clinical trials. Even after approval, each year, vaccination batches are evaluated for safety and stability to guarantee compliance with regulatory requirements. Furthermore, the longer the deadlines, the greater the production cost, which restricts new manufacturers from entering the market, stifling growth.
Discover how to stay ahead
Our 620+ page report provides 640+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccine Sales Market. See how to exploit the opportunities.
Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter’s Five Forces, SWOT Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and sub-markets
Indication
• Pneumococcal
• Rotavirus
• Influenza
• Hepatitis
• COVID-19
• Measles
• Mumps & Varicella
• Typhoid
• Meningococcal
• DPT
• Others
Route of Administration
• Intramuscular
• Subcutaneous
• Oral
Type
• Inactivated
• Live Attenuated
• Toxoid
• Recombinant/Conjugate/Subunit
Distribution Channel
• Hospital & Retail Pharmacies
• Government Suppliers
• Others
Age Group
• Pediatrics
• Adults
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
By Region
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
Need industry data? Please contact us today.
Leading companies and the potential for market growth
Overall world revenue for Vaccine Sales Market will surpass $xx billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Vaccine Sales market. Some of the companies profiled in this report include Bavarian Nordic, Bharat Biotech, CSL Limited, Daiichi Sankyo Co., Emergent BioSolutions Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J&J, Merck Co., Inc., Mitsubishi Tanabe Pharma Corporation, Moderna, Inc., Novavax, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Sinopharm, SINOVAC, and Takeda Pharmaceutical Company Limited among other prominent players.
How the Vaccine Sales Market report helps you
In summary, our 620+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Vaccine Sales Market, with forecasts for 11 indications, 3 route of administration, 4 types, 3 distribution channel, and 2 age groups , each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 5 regional and 20 key national markets– See forecasts for the Vaccine Sales market in North America, Europe, Asia Pacific, and Rest of the World. These regional markets have been further bifurcated by countries including US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, South Korea, and South-East Asia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the companies involved in the Vaccine Sales Market. Some of the company’s profiled in this report include Bavarian Nordic, Bharat Biotech, CSL Limited, Daiichi Sankyo Co., Emergent BioSolutions Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J&J, Merck Co., Inc., Mitsubishi Tanabe Pharma Corporation, Moderna, Inc., Novavax, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Sinopharm, SINOVAC, and Takeda Pharmaceutical Company Limited, among other prominent players.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Vaccine Sales Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Vaccine Sales Market Report 2022-2032: Forecasts by Indication (Pneumococcal, Rotavirus, Influenza, Hepatitis, COVID-19, Measles, Mumps & Varicella, Typhoid, Meningococcal, DPT, Others), by Route of Administration (Intramuscular, Subcutaneous, Oral), by Type (Inactivated, Live Attenuated, Toxoid, Recombinant/Conjugate/Subunit), by Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others), by Age Group (Paediatrics, Adults) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Introduction to Vaccine Sales Market
1.1 Vaccine Technologies
1.1.1 Live-Attenuated Vaccines
1.1.2 Inactivated Vaccines
1.1.3 Toxoid Vaccines
1.1.4 Subunit Vaccines
1.1.5 Virus-Like Particles (VLP) Vaccines
1.1.6 Bacterial Outer Membrane Vesicle (OMV) Vaccines
1.2 Platform-based Vaccines
1.2.1 DNA Vaccines
1.2.2 mRNA Vaccines
1.2.3 Viral Vector Vaccines
1.3 Vaccine Sales Market Definition
1.4 Why You Should Read This Report
1.5 What This Report Delivers
1.6 Key Questions Answered By This Analytical Report Include:
1.7 Who is This Report For?
1.8 Methodology
1.8.1 COVID-19 Impact: Recovery Scenarios
1.8.2 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQs)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2 Executive Summary
2.1 COVID-19 Vaccine Tracker
2.2 Top Recipients of COVID-19 R&D Funding
2.3 North America Leading the Overall Vaccines Market
2.4 Strong Portfolio has Propelled Sanofi & Pfizer to Dominate the Worldwide Vaccines Market
3 Global Vaccine Sales Market Dynamics
3.1 COVID-19 Impact on the Vaccine Sales Market
3.2 Current Trends in the Vaccine Sales Market
3.3 Market Driving Factors
3.3.1 Rising Focus and Government Support on Immunization Programs
3.3.2 Growing Investment in Vaccine Development
3.3.3 Increasing Company Initiatives to Enhance Vaccine R&D
3.3.4 High Prevalence of Infectious Diseases
3.3.5 Technological Advancements in Vaccine Administration
3.3.6 Rapid Need of Immunization
3.3.7 Strong Supply Backed Up by Robust R&D to Drive the Market
3.4 Market Restraining Factors
3.4.1 Inadequate Reimbursement Coverage
3.4.2 High Cost of Vaccine Development
3.4.3 Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
3.4.4 Stringent Government Regulations for Approval
3.4.5 Inadequate Access to Vaccines
3.4.6 Product Recalls
3.5 Opportunities in the Global Market
3.5.1 High Growth Prospects in Emerging Markets
3.5.2 Focus on Therapeutic Vaccines
3.5.3 Use of Adjuvants in Vaccines
3.5.4 Government Support for Future Vaccine R&D
3.6 SWOT Analysis
3.6.1 Strengths
3.6.1.1 Growing Demand from Emerging Economies
3.6.1.2 Prevention is Better Than Cure
3.6.1.3 Growing Vaccination Awareness to Boost Market Growth
3.6.2 Weaknesses
3.6.2.1 Strong Entry Barriers to Challenge Market Growth
3.6.2.2 Capital Intensive Business
3.6.3 Opportunities
3.6.3.1 Technological Advancements
3.6.3.2 Innovations in Vaccine Market
3.6.4 Threats
3.6.4.1 Maximum Market Share Captured by Few Global Vaccine Manufacturers
3.6.4.2 Productivity Gap
3.7 PEST Analysis
4 Global Vaccine Sales Market Analysis
4.1 Global Market Outlook
4.2 Global Market Size Estimation and Forecast
4.2.1 Pre-COVID-19 Market Scenario
4.2.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
5 Global Vaccine Sales Market Analysis by Region
5.1 North America
5.2 Europe
5.3 Asia Pacific
5.4 Latin America
5.5 MEA
5.6 Regional Market Size Estimation and Forecast
5.6.1 Pre-COVID-19 Market Scenario
5.6.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
6 Global Vaccine Sales Market Analysis by Indication
6.1 Segment Overview
6.2 Pneumococcal
6.3 Rotavirus
6.4 Influenza
6.5 Hepatitis
6.6 COVID-19
6.7 Measles
6.8 Mumps & Varicella
6.9 Typhoid
6.10 Meningococcal
6.11 DPT
6.12 Global Market Size Estimation and Forecast by Indication
6.12.1 Pre-COVID-19 Market Scenario
6.12.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
7 Global Vaccine Sales Market Analysis by Route of Administration
7.1 Segment Overview
7.2 Intramuscular
7.3 Subcutaneous
7.4 Oral
7.5 Global Market Size Estimation and Forecast by Route of Administration
7.5.1 Pre-COVID-19 Market Scenario
7.5.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
8 Global Vaccine Sales Market Analysis by Type
8.1 Segment Overview
8.2 Inactivated
8.3 Live Attenuated
8.4 Toxoid
8.5 Recombinant/Conjugate/Subunit
8.6 Global Market Size Estimation and Forecast by Type
8.6.1 Pre-COVID-19 Market Scenario
8.6.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
9 Global Vaccine Sales Market Analysis by Distribution Channel
9.1 Segment Overview
9.2 Hospital & Retail Pharmacies
9.3 Government Suppliers
9.4 Global Market Size Estimation and Forecast by Distribution Channel
9.4.1 Pre-COVID-19 Market Scenario
9.4.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
10 Global Vaccine Sales Market Analysis by Age Group
10.1 Segment Overview
10.2 Pediatrics
10.3 Adults
10.4 Global Market Size Estimation and Forecast by Age Group
10.4.1 Pre-COVID-19 Market Scenario
10.4.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis
11 North America Vaccine Sales Market
11.1 Introduction
11.2 North America Vaccine Sales Market by Country, Forecast 2022-2032
11.3 North America Vaccine Sales Market Forecast by Indication
11.4 North America Vaccine Sales Market Forecast by Route of Administration
11.5 North America Vaccine Sales Market Forecast by Type
11.6 North America Vaccine Sales Market Forecast by Distribution Channel
11.7 North America Vaccine Sales Market Forecast by Age Group
11.8 U.S. Vaccine Sales Market Forecast, 2022-2032
11.8.1 Introduction
11.8.2 U.S. Vaccine Sales Market Revenue, 2022-2032
11.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): U.S. Vaccine Sales Market Forecast, 2022-2032
11.9 Canada Vaccine Sales Market Forecast, 2022-2032
11.9.1 Introduction
11.9.2 Canada Vaccine Sales Market Revenue, 2022-2032
11.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Canada Vaccine Sales Market Forecast, 2022-2032
12 Europe Vaccine Sales Market
12.1 Introduction
12.2 Europe Vaccine Sales Market by Country, Forecast 2022-2032
12.3 Europe Vaccine Sales Market Forecast by Indication
12.4 Europe Vaccine Sales Market Forecast by Route of Administration
12.5 Europe Vaccine Sales Market Forecast by Type
12.6 Europe Vaccine Sales Market Forecast by Distribution Channel
12.7 Europe Vaccine Sales Market Forecast by Age Group
12.8 Germany Vaccine Sales Market Forecast, 2022-2032
12.8.1 Germany Well Positioned with an Established Healthcare System
12.8.2 Germany Vaccine Sales Industry Analysis
12.8.3 Germany Vaccine Sales Market Revenue, 2022-2032
12.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Germany Vaccine Sales Market Forecast, 2022-2032
12.9 UK Vaccine Sales Market Forecast, 2022-2032
12.9.1 UK Vaccine Sales Industry Analysis
12.9.2 Technological Advancements to Fuel Market Growth
12.9.3 Need to Invest in Vaccines to Offer Lucrative Growth Opportunities
12.9.4 UK Vaccine Sales Market Revenue, 2022-2032
12.9.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): UK Vaccine Sales Market Forecast, 2022-2032
12.10 France Vaccine Sales Market Forecast, 2022-2032
12.10.1 France Vaccine Sales Industry Analysis
12.10.2 France Vaccine Sales Market Revenue, 2022-2032
12.10.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): France Vaccine Sales Market Forecast, 2022-2032
12.11 Italy Vaccine Sales Market Forecast, 2022-2032
12.11.1 Italy Vaccine Sales Industry Analysis
12.11.2 Italy Vaccine Sales Market Revenue, 2022-2032
12.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Italy Vaccine Sales Market Forecast, 2022-2032
12.12 Spain Vaccine Sales Market Forecast, 2022-2032
12.12.1 Spain Vaccine Sales Market Revenue, 2022-2032
12.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Spain Vaccine Sales Market Forecast, 2022-2032
12.13 Russia Vaccine Sales Market Forecast, 2022-2032
12.13.1 Impact on Sputnik V Due to Russia Invasion of Ukraine
12.13.2 Russia Vaccine Sales Market Revenue, 2022-2032
12.13.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Russia Vaccine Sales Market Forecast, 2022-2032
12.14 Rest of Europe Vaccine Sales Market Forecast, 2022-2032
12.14.1 Rest of Europe Vaccine Sales Market Revenue, 2022-2032
12.14.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Europe Vaccine Sales Market Forecast, 2022-2032
13 Asia Pacific Vaccine Sales Market
13.1 Introduction
13.2 Asia Pacific Vaccine Sales Market by Country, Forecast 2022-2032
13.3 Asia Pacific Vaccine Sales Market Forecast by Indication
13.4 Asia Pacific Vaccine Sales Market Forecast by Route of Administration
13.5 Asia Pacific Vaccine Sales Market Forecast by Type
13.6 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel
13.7 Asia Pacific Vaccine Sales Market Forecast by Age Group
13.8 Japan Vaccine Sales Market Forecast, 2022-2032
13.8.1 Japan Vaccine Sales Industry Analysis
13.8.2 Japan Vaccine Sales Market Revenue, 2022-2032
13.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Japan Vaccine Sales Market Forecast, 2022-2032
13.9 China Vaccine Sales Market Forecast, 2022-2032
13.9.1 China Vaccine Sales Industry Analysis
13.9.2 China Vaccine Sales Market Revenue, 2022-2032
13.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): China Vaccine Sales Market Forecast, 2022-2032
13.10 India Vaccine Sales Market Forecast, 2022-2032
13.10.1 India Vaccine Sales Industry Analysis
13.10.2 Indian Vaccines Industry Has a Huge Internal Market to be Serviced
13.10.3 Research and Development in India for Vaccines Innovation and Invention
13.10.4 India Vaccine Sales Market Revenue, 2022-2032
13.10.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): India Vaccine Sales Market Forecast, 2022-2032
13.11 Australia Vaccine Sales Market Forecast, 2022-2032
13.11.1 Australia Vaccine Sales Industry Analysis
13.11.2 Australia Vaccine Sales Market Revenue, 2022-2032
13.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Australia Vaccine Sales Market Forecast, 2022-2032
13.12 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032
13.12.1 Rest of Asia Pacific Vaccine Sales Market Revenue, 2022-2032
13.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032
14 Latin America Vaccine Sales Market
14.1 Introduction
14.2 Latin America Vaccine Sales Market by Country, Forecast 2022-2032
14.3 Latin America Vaccine Sales Market Forecast by Indication
14.4 Latin America Vaccine Sales Market Forecast by Route of Administration
14.5 Latin America Vaccine Sales Market Forecast by Type
14.6 Latin America Vaccine Sales Market Forecast by Distribution Channel
14.7 Latin America Vaccine Sales Market Forecast by Age Group
14.8 Brazil Vaccine Sales Market Forecast, 2022-2032
14.8.1 Brazil Vaccine Sales Industry Analysis
14.8.2 Public Market Accounts for 90% of Demand
14.8.3 PAHO Announced 2 Centers in Argentina and Brazil as Regional Hubs for Development of mRNA-based Vaccine Manufacturing
14.8.4 Brazil Vaccine Sales Market Revenue, 2022-2032
14.8.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): Brazil Vaccine Sales Market Forecast, 2022-2032
14.9 Mexico Vaccine Sales Market Forecast, 2022-2032
14.9.1 Mexico Vaccine Sales Industry Analysis
14.9.2 Emerging Region Across Latin America
14.9.3 Mexico Vaccine Sales Market Revenue, 2022-2032
14.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Mexico Vaccine Sales Market Forecast, 2022-2032
14.10 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032
14.10.1 Rest of Latin America Vaccine Sales Market Revenue, 2022-2032
14.10.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Latin America Vaccine Sales Market Forecast, 2022-2032
15 Middle East and Africa Vaccine Sales Market
15.1 Introduction
15.2 Middle East and Africa Vaccine Sales Market by Country, Forecast 2022-2032
15.3 Middle East and Africa Vaccine Sales Market Forecast by Indication
15.4 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration
15.5 Middle East and Africa Vaccine Sales Market Forecast by Type
15.6 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel
15.7 Middle East and Africa Vaccine Sales Market Forecast by Age Group
15.8 GCC Vaccine Sales Market Forecast, 2022-2032
15.8.1 GCC Vaccine Sales Industry Analysis
15.8.2 Gulf Nations Have United to Support COVAX
15.8.3 GCC Vaccine Sales Market Revenue, 2022-2032
15.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): GCC Vaccine Sales Market Forecast, 2022-2032
15.9 South Africa Vaccine Sales Market Forecast, 2022-2032
15.9.1 COVAX Delivering Vaccines to Africa
15.9.2 South Africa Vaccine Sales Industry Analysis
15.9.3 South Africa Vaccine Sales Market Revenue, 2022-2032
15.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): South Africa Vaccine Sales Market Forecast, 2022-2032
15.10 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032
15.10.1 Rest of Middle East and Africa Vaccine Sales Market Revenue, 2022-2032
15.10.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032
16 Company Profiles
16.1 Bavarian Nordic
16.1.1 Company Snapshot
16.1.2 Company Overview
16.1.3 Financial Analysis
16.1.3.1 Net Revenue, 2015-2020
16.1.3.2 R&D Expenses, 2015-2020
16.1.3.3 Gross Profit, 2015-2020
16.1.4 Product Benchmarking
16.1.5 Recent Developments till December 2021
16.2 Bharat Biotech
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Product Benchmarking
16.2.4 Recent Developments till December 2021
16.3 CSL Limited
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Net Revenue, 2015-2020
16.3.3.2 R&D Expenses, 2015-2020
16.3.3.3 Gross Profit, 2015-2020
16.3.4 Product Benchmarking
16.3.5 Recent Developments till December 2021
16.4 Emergent BioSolutions Inc.
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2015-2020
16.4.3.2 R&D Expenses, 2015-2020
16.4.3.3 Gross Profit, 2015-2020
16.4.4 Product Benchmarking
16.4.5 Recent Developments till December 2021
16.5 GlaxoSmithKline plc
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2015-2020
16.5.3.2 R&D Expenses, 2015-2020
16.5.3.3 Gross Profit, 2015-2020
16.5.4 Product Benchmarking
16.5.5 Recent Developments till December 2021
16.6 Inovio Pharmaceuticals, Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2015-2020
16.6.3.2 R&D Expenses, 2015-2020
16.6.3.3 Gross Profit, 2015-2020
16.6.4 Product Benchmarking
16.6.5 Recent Developments till December 2021
16.7 J&J
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2015-2020
16.7.3.2 R&D Expenses, 2015-2020
16.7.3.3 Gross Profit, 2015-2020
16.7.4 Product Benchmarking
16.7.5 Recent Developments till December 2021
16.8 Merck Co., Inc.
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Net Revenue, 2015-2020
16.8.3.2 R&D Expenses, 2015-2020
16.8.3.3 Gross Profit, 2015-2020
16.8.4 Product Benchmarking
16.8.5 Recent Developments till December 2021
16.9 Mitsubishi Tanabe Pharma Corporation
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Product Benchmarking
16.9.4 Recent Developments till December 2021
16.10 Moderna, Inc.
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2015-2020
16.10.3.2 R&D Expenses, 2015-2020
16.10.3.3 Gross Profit, 2015-2020
16.10.4 Product Benchmarking
16.10.5 Recent Developments till December 2021
16.11 Novavax
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2015-2020
16.11.3.2 R&D Expenses, 2015-2020
16.11.3.3 Gross Profit, 2015-2020
16.11.4 Product Benchmarking
16.11.5 Recent Developments till December 2021
16.12 Panacea Biotec Ltd.
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Product Benchmarking
16.13 Pfizer Inc.
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Net Revenue, 2015-2020
16.13.3.2 R&D Expenses, 2015-2020
16.13.3.3 Gross Profit, 2015-2020
16.13.4 Product Benchmarking
16.13.5 Recent Developments till December 2021
16.14 Sanofi
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Net Revenue, 2015-2020
16.14.3.2 R&D Expenses, 2015-2020
16.14.3.3 Gross Profit, 2015-2020
16.14.4 Product Benchmarking
16.14.5 Recent Developments till December 2021
16.15 Serum Institute of India Pvt. Ltd.
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Product Benchmarking
16.15.4 Recent Developments till December 2021
16.16 AstraZeneca PLC
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Financial Analysis
16.16.3.1 Net Revenue, 2015-2020
16.16.3.2 R&D Expenses, 2015-2020
16.16.3.3 Gross Profit, 2015-2020
16.16.4 Product Benchmarking
16.16.5 Recent Developments till December 2021
16.17 Sinopharm
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Product Benchmarking
16.18 SINOVAC
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Financial Analysis
16.18.3.1 Net Revenue, 2015-2020
16.18.3.2 R&D Expenses, 2015-2020
16.18.3.3 Gross Profit, 2015-2020
16.18.4 Product Benchmarking
16.18.5 Recent Developments till December 2021
16.19 Takeda Pharmaceutical Company Limited
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Financial Analysis
16.19.3.1 Net Revenue, 2015-2020
16.19.3.2 R&D Expenses, 2015-2020
16.19.3.3 Gross Profit, 2015-2020
16.19.4 Product Benchmarking
16.19.5 Recent Developments till December 2021
16.20 Daiichi Sankyo Co., Ltd.
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Financial Analysis
16.20.3.1 Net Revenue, 2015-2020
16.20.3.2 R&D Expenses, 2015-2020
16.20.3.3 Gross Profit, 2015-2020
16.20.4 Product Benchmarking
16.20.5 Recent Developments till December 2021
17 Conclusion and Recommendations
17.1 Concluding Remarks
17.2 Recommendations
List of Tables
Table 1 Global Vaccine Sales Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Global COVID-19 Vaccine Tracker by Company & Vaccine Type
Table 3 Vaccine Sales Market 2022 - 2032
Table 4 Vaccine Sales Market Forecast, 2022 - 2032: "V" Shaped Recovery
Table 5 Vaccine Sales Market Forecast, 2022 - 2032: "U" Shaped Recovery
Table 6 Vaccine Sales Market Forecast, 2022 - 2032: "W" Shaped Recovery
Table 7 Vaccine Sales Market Forecast, 2022 - 2032: "L" Shaped Recovery
Table 8 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 9 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 10 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 11 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 12 Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 13 Vaccine Types
Table 14 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 15 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 16 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 17 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 18 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 19 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 20 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 21 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 22 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 23 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 24 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 25 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 26 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 27 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 28 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 29 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 30 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 31 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 32 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 33 Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 34 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 35 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 36 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 37 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 38 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 39 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 40 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 41 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 42 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 43 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 44 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 45 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 46 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 47 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 48 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 49 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 50 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 51 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 52 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 53 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 54 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 55 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 56 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 57 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 58 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 59 North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 60 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 61 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 62 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 63 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 64 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 65 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 66 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 67 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 68 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 69 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 70 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 71 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 72 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 73 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 74 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 75 Europe Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 76 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 77 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 78 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 79 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 80 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 81 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 82 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 83 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 84 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 85 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 86 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 87 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 88 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 89 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 90 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 91 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 92 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 93 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 94 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 95 Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 96 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 97 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 98 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 99 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 100 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 101 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 102 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 103 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 104 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 105 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 106 UK Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 107 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 108 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 109 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 110 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 111 France Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 112 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 113 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 114 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 115 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 116 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 117 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 118 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 119 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 120 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 121 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 122 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 123 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 124 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 125 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 126 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 127 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 128 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 129 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 130 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 131 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 132 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 133 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 134 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 135 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 136 Asia Pacific Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 137 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 138 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 139 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 140 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 141 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 142 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 143 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 144 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 145 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 146 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 147 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 148 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 149 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 150 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 151 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 152 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 153 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 154 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 155 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 156 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 157 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 158 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 159 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 160 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 161 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 162 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 163 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 164 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 165 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 166 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 167 China Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 168 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 169 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 170 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 171 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 172 India Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 173 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 174 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 175 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 176 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 177 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 178 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 179 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 180 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 181 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 182 Rest of APAC Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 183 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 184 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 185 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 186 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 187 Latin America Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 188 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 189 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 190 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 191 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 192 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 193 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 194 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 195 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 196 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 197 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 198 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 199 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 200 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 201 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 202 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 203 Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 204 Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 205 Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 206 Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 207 Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 208 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 209 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 210 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 211 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 212 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 213 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 214 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 215 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 216 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 217 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 218 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 219 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 220 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 221 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 222 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 223 Rest of LATAM Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 224 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 225 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 226 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 227 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 228 MEA Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 229 MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 230 MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 231 MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 232 MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 233 MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 234 MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 235 MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 236 MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 237 MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 238 MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 239 MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 240 MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 241 MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 242 MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 243 MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 244 MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
Table 245 MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 246 MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 247 MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 248 MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 249 MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 250 MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 251 MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 252 MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 253 MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 254 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 255 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 256 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 257 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 258 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 259 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 260 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 261 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 262 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 263 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 264 Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 265 Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
Table 266 Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
Table 267 Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
Table 268 Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
Table 269 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 270 Bavarian Nordic: Product Benchmarking
Table 271 Bavarian Nordic: Recent Developments till December 2021
Table 272 Bharat Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 273 Bharat Biotech: Product Benchmarking
Table 274 Bharat Biotech: Recent Developments till December 2021
Table 275 CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 276 CSL Limited: Product Benchmarking
Table 277 CSL Limited: Recent Developments till December 2021
Table 278 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 279 Emergent BioSolutions Inc.: Product Benchmarking
Table 280 Emergent BioSolutions Inc.: Recent Developments till December 2021
Table 281 GlaxoSmithKline plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 282 GlaxoSmithKline plc: Product Benchmarking
Table 283 GlaxoSmithKline plc: Recent Developments till December 2021
Table 284 Inovio Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 285 Inovio Pharmaceuticals, Inc.: Product Benchmarking
Table 286 Inovio Pharmaceuticals, Inc.: Recent Developments till December 2021
Table 287 J&J: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 288 J&J: Product Benchmarking
Table 289 J&J: Recent Developments till December 2021
Table 290 Merck Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 291 Merck Co., Inc.: Product Benchmarking
Table 292 Merck Co., Inc.: Recent Developments till December 2021
Table 293 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 294 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 295 Mitsubishi Tanabe Pharma Corporation: Recent Developments till December 2021
Table 296 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 297 Moderna, Inc.: Product Benchmarking
Table 298 Moderna, Inc.: Recent Developments till December 2021
Table 299 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 300 Novavax: Product Benchmarking
Table 301 Novavax: Recent Developments till December 2021
Table 302 Panacea Biotec Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 303 Panacea Biotec Ltd.: Product Benchmarking
Table 304 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 305 Pfizer Inc.: Product Benchmarking
Table 306 Pfizer Inc.: Recent Developments till December 2021
Table 307 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 308 Sanofi: Product Benchmarking
Table 309 Sanofi: Recent Developments till December 2021
Table 310 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 311 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 312 Serum Institute of India Pvt. Ltd.: Recent Developments till December 2021
Table 313 AstraZeneca PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 314 AstraZeneca PLC: Product Benchmarking
Table 315 AstraZeneca PLC: Recent Developments till December 2021
Table 316 Sinopharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 317 Sinopharm: Product Benchmarking
Table 318 SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 319 SINOVAC: Product Benchmarking
Table 320 SINOVAC: Recent Developments till December 2021
Table 321 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 322 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 323 Takeda Pharmaceutical Company Limited: Recent Developments till December 2021
Table 324 Daiichi Sankyo Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 325 Daiichi Sankyo Co., Ltd.: Product Benchmarking
Table 326 Daiichi Sankyo Co., Ltd.: Recent Developments till December 2021
List of Figures
Figure 1 Global Vaccine Sales Market: Market Segmentation
Figure 2 Top Recipients of COVID-19 R&D Funding in US$ million (As of March 2021)
Figure 3 Global Vaccine Sales Market Trends
Figure 1 Global Vaccine Sales Market: SWOT Analysis
Figure 2 PEST Analysis
Figure 3 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 4 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 5 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 6 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 7 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 8 Global Vaccine Sales Market Share Forecast by Region 2022, 2027, 2032 (%)
Figure 9 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 10 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 11 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 12 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 13 Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 14 Global Vaccine Sales Market Share Forecast by Indication: 2022, & 2032 (%)
Figure 15 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
Figure 16 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 17 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 18 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 19 Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 20 Global Vaccine Sales Market Share Forecast by Route of Administration: 2022, 2027, 2032 (%)
Figure 21 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 22 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 23 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 24 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 25 Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 26 Global Vaccine Sales Market Share Forecast by Type: 2022, 2027, 2032 (%)
Figure 27 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 28 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 29 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 30 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 31 Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 32 Global Vaccine Sales Market Share Forecast by Distribution Channel: 2022, 2027, 2032 (%)
Figure 33 Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 34 Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 35 Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 36 Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 37 Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 38 Global Vaccine Sales Market Share Forecast by Age Group: 2022, 2027, 2032 (%)
Figure 39 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 40 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 41 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 42 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 43 Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 44 North America Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
Figure 45 North America Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
Figure 46 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
Figure 47 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 48 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 49 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 50 North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 51 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 52 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 53 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 54 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 55 North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 56 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 57 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 58 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 59 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 60 North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 61 North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 62 North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 63 North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 64 North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 65 North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 66 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 67 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 68 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 69 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 70 North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 71 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 72 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 73 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 74 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 75 U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 76 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 77 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 78 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 79 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 80 Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 81 Europe Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
Figure 82 Europe Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
Figure 83 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
Figure 84 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 85 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 86 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 87 Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 88 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 89 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 90 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 91 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 92 Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 93 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 94 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 95 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 96 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 97 Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 98 Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 99 Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 100 Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 101 Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 102 Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 103 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 104 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 105 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 106 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 107 Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 108 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 109 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 110 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 111 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 112 Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 113 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 114 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 115 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 116 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 117 UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 118 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 120 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 121 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 122 France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 123 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 124 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 125 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 126 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 127 Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 128 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 129 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 130 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 131 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 132 Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 133 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 134 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 135 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 136 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 137 Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 138 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 139 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 140 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 141 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 142 Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 143 Asia Pacific Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
Figure 144 Asia Pacific Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
Figure 145 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
Figure 146 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 147 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 148 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 149 Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 150 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 151 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 152 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 153 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 154 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 155 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 156 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 157 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 158 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 159 Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 160 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 161 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 162 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 163 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 164 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 165 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 166 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 167 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 168 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 169 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 170 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 171 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 172 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 173 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 174 Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 175 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 176 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 177 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 178 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 179 China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 180 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 181 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 182 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 183 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 184 India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 185 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 186 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 187 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 188 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 189 Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 190 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 191 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 192 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 193 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 194 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 195 Latin America Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
Figure 196 Latin America Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
Figure 197 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
Figure 198 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 199 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 200 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 201 Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 202 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 203 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 204 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 205 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 206 Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 207 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 208 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 209 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 210 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 211 Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 212 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 213 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 214 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 215 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 216 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 217 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 218 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 219 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 220 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 221 Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 222 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 223 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 224 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 225 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 226 Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 227 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 228 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 229 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 230 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 231 Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 232 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 233 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 234 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 235 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 236 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 237 Middle East and Africa Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
Figure 238 Middle East and Africa Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
Figure 239 Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
Figure 240 Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 241 Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 242 Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 243 Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 244 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 245 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 246 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 247 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 248 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 249 Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 250 Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 251 Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 252 Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 253 Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 254 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 255 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 256 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 257 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 258 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 259 Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 260 Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 261 Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 262 Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 263 Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 264 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 265 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 266 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 267 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 268 GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 269 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 270 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 271 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 272 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 273 South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 274 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 275 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “V” Shaped Recovery
Figure 276 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “U” Shaped Recovery
Figure 277 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “W” Shaped Recovery
Figure 278 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): “L” Shaped Recovery
Figure 279 Bavarian Nordic: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 280 Bavarian Nordic: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 281 Bavarian Nordic: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 282 CSL Limited: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 283 CSL Limited: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 284 CSL Limited: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 285 Emergent BioSolutions Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 286 Emergent BioSolutions Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 287 Emergent BioSolutions Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 288 GlaxoSmithKline plc: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 289 GlaxoSmithKline plc: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 290 GlaxoSmithKline plc: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 291 Inovio Pharmaceuticals, Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 292 Inovio Pharmaceuticals, Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 293 Inovio Pharmaceuticals, Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 294 J&J: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 295 J&J: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 296 J&J: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 297 Merck Co., Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 298 Merck Co., Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 299 Merck Co., Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 300 Moderna, Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 301 Moderna, Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 302 Moderna, Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 303 Novavax: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 304 Novavax: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 305 Novavax: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 306 Pfizer Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 307 Pfizer Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 308 Pfizer Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 309 Sanofi: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 310 Sanofi: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 311 Sanofi: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 312 AstraZeneca PLC: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 313 AstraZeneca PLC: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 314 AstraZeneca PLC: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 315 SINOVAC: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 316 SINOVAC: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 317 SINOVAC: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 318 Takeda Pharmaceutical Company Limited: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 319 Takeda Pharmaceutical Company Limited: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 320 Takeda Pharmaceutical Company Limited: Gross Profit, 2015-2020 (US$ billion, AGR %)
Figure 321 Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2020 (US$ billion, AGR %)
Figure 322 Daiichi Sankyo Co., Ltd.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
Figure 323 Daiichi Sankyo Co., Ltd.: Gross Profit, 2015-2020 (US$ billion, AGR %)
Companies Profiled in the Report
AstraZeneca PLC
Bavarian Nordic
Bharat Biotech
CSL Limited
Daiichi Sankyo Co.
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Inovio Pharmaceuticals, Inc.
J&J
Merck Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Moderna, Inc.
Novavax
Panacea Biotec Ltd.
Pfizer Inc.
Sanofi
Serum Institute of India Pvt. Ltd.
Sinopharm
SINOVAC
Takeda Pharmaceutical Company Limited
List of Other Companies
Abeona Therapeutics
Acucela
Adaptimmune Therapeutics
Autolus
AveXis
BioCancell
Biomay
Biomiga
BioReliance
Biotec Services International
Celladon
Cellectis
Cellular Biomedicine Group
Delphi Genetics
Department of Neuroscience, University of Minnesota
Desktop Genetics
DNAtrix
Elixirgen Scientific
Epeius Biotechnologies
EUFETS
Eurofins Genomics
European Society of Gene and Cell Therapy
GEG Tech
Genable Technologies
Immune Design
Immune Technology
ImmunoGenes
Immunomic Therapeutics
Inbiomed
Indiana University Vector Production Facility
VIVEbiotech
Voyager Therapeutics
Waisman Biomanufacturing
Xpress Biologics
List of Organizations
Association of British Pharmaceutical Industry (ABPI)
Central Drugs Standard Control Organization (CDSCO)
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
European Commission
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Indian Drug Manufacturer's Association (IDMA)
International Society of Pharmaceutical Engineering (IPSE)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer's Association (KPMA)
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Industry and Information Technology (MIIT)
Pharmaceutical and Medical Devices Agency (PMDA)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
